Aktis Oncology, Inc. cotiza a 17.34 USD y tiene una capitalización bursátil de $964M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2024-11 |
|---|---|---|---|---|
| Real | — | — | $-0.38 | $-0.04 |
| Estimado | $-0.46 | $-0.43 | $-0.33 | $-0.08 |
| Sorpresa | — | — | -15.2% | +50.0% |
| Métrica | AKTS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | — | -32.0% | — |
| Current Ratio | 7.37 | 2.84 | +4.53 |
| Debt / Equity | — | 0.28 | — |